DiaMedica Therapeutics raised $30 million in a private placement to accelerate its preeclampsia and fetal growth restriction pipeline, led by current investors.
DiaMedica Therapeutics Inc. announced definitive agreements for a $30.1 million private placement of common shares. The funds will support the company’s operations and upcoming milestones, including an IND application and a Phase 2b study for DM199. This financing enables rapid development efforts for conditions with no approved treatments
Who to call at DiaMedica Therapeutics, and when
A new round usually means DiaMedica Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day DiaMedica Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at DiaMedica Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
DiaMedica Therapeutics
Location
301 CARLSON PARKWAY
Minneapolis, Minnesota, United States
About
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment DiaMedica Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MinneapolisBiotechnologyHealth CareTherapeuticsBiopharma